A pilot study of Rhodiola rosea (Rhodax®) for generalized anxiety disorder (GAD)
A pilot study of Rhodiola rosea (Rhodax®) for generalized anxiety disorder (GAD)
复制标题
DOI：
10.1089/acm.2007.7117
复制
发表时间：
2008-03-01
影响因子：
2.6
通讯作者：
Feusner, Jamie D.
中科院分区：
文献类型：
--
作者：
Bystritsky, Alexander;Kerwin, Lauren;Feusner, Jamie D.
背景：红景天是一种草药补充剂，俄罗斯和世界其他地方的许多人几十年来一直使用它来缓解日常焦虑、抑郁和失眠。玫瑰红是否能有效减少临床样本中的类似症状尚不清楚。本试验研究的目的是评估玫瑰红是否能有效减轻广泛性焦虑症 (GAD) 的症状。方法：从 2005 年 11 月至 2006 年 5 月期间，从 UCLA 焦虑症项目招募了十 (10) 名经 DSM-IV 诊断为 GAD 的参与者，年龄在 34 至 55 岁之间。参与者每天接受总剂量为 340 毫克的玫瑰红提取物，连续 10 个月。几周。评估包括汉密尔顿焦虑评定量表 (HARS)、四维焦虑和抑郁量表以及严重性/改善量表的临床总体印象。结果：使用红玫瑰治疗的个体在终点时的平均 HARS 评分显着下降（t = 3.27，p = 0.01）。不良事件的严重程度一般为轻度或中度，最常见的是头晕和口干。结论：R.rosea 发现 GAD 症状显着改善，HARS 评分降低与临床试验中发现的结果相似。这些初步发现值得在临床样本中进一步探索红玫瑰的治疗方法。
Background: Rhodiola rosea is an herbal supplement that many in the general population in Russia and elsewhere in the world have used for decades to alleviate everyday anxiety, depression, and insomnia. Whether R. rosea is effective in reducing similar symptoms in clinical samples is unknown. The goal of this pilot study was to evaluate whether R. rosea is effective in reducing symptoms of generalized anxiety disorder (GAD).Method: Ten (10) participants with a DSM-IV diagnosis of GAD, recruited from the UCLA Anxiety Disorders Program and between the ages of 34 and 55, were enrolled in this study from November 2005 to May 2006. Participants received a total daily dose of 340 mg of R. rosea extract for 10 weeks. Assessments included the Hamilton Anxiety Rating Scale (HARS), the Four-Dimensional Anxiety and Depression Scale, and the Clinical Global Impressions of Severity/Improvement Scale.Results: Individuals treated with R. rosea showed significant decreases in mean HARS scores at endpoint (t = 3.27, p = 0.01). Adverse events were generally mild or moderate in severity, the most common being dizziness and dry mouth.Conclusions: Significant improvement in GAD symptoms was found with R. rosea, with a reduction in HARS scores similar to that found in clinical trials. These preliminary findings warrant further exploration of treatment with R. rosea in clinical samples.